Education
About Us
Working with TipRanks
Follow Us
Alpha Teknova (TKNO)
NASDAQ:TKNO
Earnings Data
Report Date
May 13, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call portrayed clear operational and financial progress: revenue growth (6th straight quarter), improved gross margins, narrower net losses and adjusted EBITDA, better free cash flow performance, growing clinical customer count and pipeline progress. Management is beginning to reinvest (~$2M) in commercial capabilities, providing a plausible path to adjusted EBITDA positivity by end of 2027 (targeting $52M–$57M annualized revenue). Key near-term risks include ongoing negative adjusted EBITDA and free cash outflow, lowered average revenue per customer from new/early-stage accounts, revenue lumpiness in Clinical Solutions, and reliance on a sustained biotech funding recovery (with a ~4-quarter lag) to accelerate revenue. Overall, the company is trending in the right direction but still requires execution and favorable market conditions to meet longer-term targets.Company Guidance
Revenue Growth and Momentum
Total revenue of $40.5M in FY2025, a 7% increase from $37.7M in FY2024; Q4 revenue $10.0M, up 8% YoY. This marks the company's sixth consecutive quarter of revenue growth.
Catalog and Lab Essentials Performance
Catalog products led growth (low double-digit growth vs 2024). Lab Essentials revenue was $31.0M in 2025, up 7% YoY; ~75% of Lab Essentials revenue came from catalog products.
Clinical Solutions Acceleration
Clinical Solutions revenue was $2.7M in Q4 2025, a 47% YoY increase, and $7.7M for FY2025, up 8% YoY. Clinical customers grew from 48 in 2024 to 60 in 2025 (25% increase).
Clinical Pipeline Traction
Supporting at least 70 therapies (up from prior year), including 5 in Phase II or later (up from 3) and 12 in Phase I (up from 10); management expects to support at least one commercial therapy by end of 2027.
Gross Margin and Profitability Improvement
Gross profit rose to $13.4M for FY2025 from $7.2M in FY2024. Gross margin improved to 33.2% for FY2025 from 19.2% in FY2024 (Q4 margin 32.5% vs 23.0% prior year); improvement driven by higher revenue and manufacturing efficiencies (adjusted for a $2.8M 2024 nonrecurring inventory charge).
Adjusted EBITDA and Net Loss Improvements
Adjusted EBITDA improved to negative $6.7M for FY2025 from negative $14.5M in FY2024 (Q4 adjusted EBITDA negative $1.8M vs negative $3.2M prior year). Net loss narrowed to $17.3M ($0.32/share) in FY2025 from $26.7M ($0.57/share) in FY2024.
Cash Flow and Balance Sheet Progress
Free cash outflow improved to negative $9.8M in FY2025 from negative $13.5M in FY2024, beating guidance of <$12M. Cash, cash equivalents and short-term investments totaled $21.3M at year-end with $13.2M gross debt.
Operational Metrics and Cost Discipline
Delivered ~95% of products on time in 2025; ~95% annual customer retention; over 3,000 customers; top 10 Lab Essentials customers represented only 18% of revenue. Headcount reduced to 158 from 173; operating expenses (ex nonrecurring) below $8M for seven consecutive quarters.
Forward-Looking Targets and Investment Plan
2026 revenue guidance of $42M–$44M (midpoint ≈ 6% growth). Company plans ~$2M incremental annual commercial investment in 2026 to accelerate growth; expects adjusted EBITDA positivity by end of 2027 at $52M–$57M annualized revenue and incremental revenue margin contribution of ~70% to the bottom line.
TKNO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TKNO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $2.28 | $2.58 | +13.16% |
Nov 06, 2025 | $4.81 | $4.71 | -2.08% |
Aug 07, 2025 | $4.34 | $4.23 | -2.53% |
May 08, 2025 | $6.37 | $6.96 | +9.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Alpha Teknova (TKNO) report earnings?
Alpha Teknova (TKNO) is schdueled to report earning on May 13, 2026, After Close (Confirmed).
What is Alpha Teknova (TKNO) earnings time?
Alpha Teknova (TKNO) earnings time is at May 13, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TKNO EPS forecast?
TKNO EPS forecast for the fiscal quarter 2026 (Q1) is -0.09.